AngioChamberTM and AngioSpongeTM are allowing to study neovascularisation. As the AngioChamberTM is a pure quantitative models especially suitable for rapid screening the AngiSpongeTM in addition allows to assess the blood capillary quality. Both models are recommended to screen new drugs for there anti-angiogenic systemic effects before entering studies agains human xenografts.
Bone is the third most common site of metastatic disease. Cancers most likely to metastasize to bone include breast, lung, prostate, thyroid and kidney. Until now, there has been a lack of in vivo models to test novel cancer therapies against bone metastases. Consequently, vivoPharm has developed propriety technology to produce a model mimicking the growth of several cancers in bone. We have optimised our analytical methods (including X-Ray and microCT systems) to correlate efficacy of therapy with changes in bone density. X-ray and microCT analysis give our clients not only excellent quantification of drug effect, but also impressive 3D pictures to visualize the effects This improved protocol is also suitable for use with breast cancer and multiple myeloma.
A NeuT (ErbB2)-driven syngeneic orthotopic tumour model for testing efficacy of anti-cancer compounds has been specially designed to inhibit ErbB2 or EGFR. Tumours of this model are characterized by a morphology and response rate to therapy similar to that experienced in cancer patients. Therefore this model is believed to present high clinical predictability. In brief, drug-selected NeuT infected mammary epithelial cell populations are introduced into mammary fat pads of BALB/c syngeneic mice which have been cleared of host tissue. Breast tumours develop within a 3 to 4 week latency period and grow rapidly. The histology of the breast tumours is comparable to those observed in MMTV-NeuT transgenic mice. Most importantly, this tumour model is to our knowledge the first oncogene-driven model with a heterogeneous therapy response within a treatment group.
